SMT Ireland to lift SNP Medical stake to up to 17.19%

Sahajanand Medical Technologies Limited said SMT Ireland will raise its holding in SNP Medical Corp. to up to 17.19% from 14.15% as at 30 September 2026, through a related-party cash acquisition costing up to USD 7.80 lakh and tentatively due for completion by 31 March 2027.

What stake will SMT Ireland acquire in SNP Medical?

SMT Ireland will increase its SNP holding by up to 3.04 percentage points, from 14.15% on 30 September 2026 to up to 17.19% after the proposed acquisition. The disclosure does not state the number of SNP shares to be acquired, but it specifies the current and post-transaction percentage holdings.

The acquisition will be paid in cash and carries a maximum cost of USD 7.80 lakh. The price per share will be determined on the basis of SNP's valuation, meaning the filing does not disclose either a fixed per-share price or the final consideration within the stated ceiling.

The proposed 17.19% holding is a minority stake, and the filing does not say SMT Ireland will obtain control, board rights or specific governance rights in SNP. SNP is described as a US medical-device startup registered in Delaware on 31 May 2022 and working on the development of medical devices.

Why is SMT Ireland's SNP Medical acquisition a related-party transaction?

SMT Ireland's acquisition is a related-party transaction because Priyanka Cohen is a promoter and non-executive director of Sahajanand Medical Technologies Limited and a director of SNP. SMT stated that the transaction will be undertaken on an arm's-length basis.

The filing identifies Ms. Cohen's roles at both companies but does not disclose her ownership interest in SNP, her involvement in approving the transaction, or the valuation method that will set the price per share. The maximum cash consideration is USD 7.80 lakh, while the final amount depends on SNP's valuation.

SMT made the announcement under Regulation 30 of the Securities and Exchange Board of India, or SEBI, Listing Obligations and Disclosure Requirements Regulations, 2015. The annexure also cites SEBI Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026, dated 30 January 2026.

SMT said the acquisition is intended to diversify its product portfolio within its existing main line of business. In its standalone results for the quarter and six months ended 30 September 2026, SMT identified cardiovascular devices as its single operating segment, including balloon catheters, cardiac stents, transcatheter aortic valve implantation, or TAVI, and occluders.

How has SNP Medical's revenue changed over three years?

SNP reported revenue of USD 3 lakh in calendar 2025, compared with USD 2.35 lakh in 2024 and USD 5.65 lakh in 2023. Revenue increased by USD 65,040 from 2024 to 2025, but 2025 revenue remained USD 2.65 lakh below the 2023 level.

The reported sequence shows a decline of USD 3.30 lakh between 2023 and 2024, followed by the increase in 2025. The figures are for SNP's calendar years, whereas SMT's cited standalone reporting period ended on 30 September 2026.

SNP's USD 3 lakh of 2025 turnover is the target's latest revenue figure disclosed in the acquisition annexure. The filing does not provide SNP's profit or loss, assets, liabilities, cash balance, research-and-development spending, order book or product-level revenue.

The announcement also does not identify the source of SNP's USD 3 lakh of 2025 revenue, such as product sales, licensing or development services. Since the share price remains subject to valuation and no earnings information is disclosed, a transaction valuation multiple cannot be calculated from the USD 7.80 lakh maximum consideration and the reported revenue.

When will SMT Ireland's SNP Medical transaction be completed?

SMT Ireland's acquisition is tentatively expected to be completed by 31 March 2027. SMT listed governmental or regulatory approvals as not applicable for the transaction, although the completion date remains tentative and the price per share is still to be determined by valuation.

The disclosure names no regulator, approval process or clearance timetable for the maximum USD 7.80 lakh cash acquisition. It also does not state whether closing depends on a valuation report, definitive agreements, SNP shareholder approval or other contractual conditions.

SMT Ireland already held 14.15% of SNP on 30 September 2026, before the proposed increase to up to 17.19%. The filing does not disclose when SMT Ireland acquired its existing stake, its jurisdiction or legal form, or how the additional investment will be accounted for in SMT's financial statements.

SMT's audit committee and board reviewed and approved the unaudited standalone results for the quarter and six months ended 30 September 2026 on 5 November 2026. Those results state that SMT operates as a single cardiovascular-devices segment, while the SNP disclosure positions the acquisition as product-portfolio diversification within that business line.

What does the filing disclose about SNP Medical's business?

SNP is a US-based medical-device startup registered in Delaware on 31 May 2022 and is working on developing medical devices. Its disclosed 2025 turnover was USD 3 lakh, compared with USD 2.35 lakh in 2024 and USD 5.65 lakh in 2023.

The filing places SNP in the medical-device industry, the same broad industry in which SMT manufactures cardiovascular devices. However, it does not name an SNP product, development programme, regulatory filing, commercial market or customer base that would explain how the additional stake supports the stated portfolio-diversification objective.

SMT's disclosed cardiovascular-device range includes balloon catheters, cardiac stents, TAVI and occluders, all within its single operating segment for the six months ended 30 September 2026. SNP's disclosure is less detailed, stating only that it is developing medical devices and has reported the three annual revenue figures through calendar 2025.

The difference in disclosed detail matters because SMT has set the transaction price by reference to SNP's valuation rather than a fixed amount per share. Until the valuation-based price and final stake are disclosed, the filing establishes only the USD 7.80 lakh maximum cost and the potential 3.04-percentage-point increase in ownership.

Conclusion

The proposed acquisition would raise SMT Ireland's minority interest in SNP from 14.15% to up to 17.19% for cash consideration of up to USD 7.80 lakh. SMT links the transaction to medical-device portfolio diversification, while identifying it as a related-party transaction because Priyanka Cohen is both an SMT promoter and non-executive director and an SNP director.

The disclosed next milestone is tentative completion by 31 March 2027. The matters to watch are the valuation-based price per SNP share, the final stake acquired, and any later disclosure of transaction conditions or SNP's products, particularly as SNP's revenue rose to USD 3 lakh in 2025 from USD 2.35 lakh in 2024 but remained below USD 5.65 lakh in 2023.